Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy

Annals of Oncology

Volumn 15, Issue 11, 2004, Pages 1627-1632

  Schneeweiss, Andreas ^a   Diel, I ^b   Hensel, M ^a   Kaul, S ^a   Sinn, H P ^a   Unnebrink, K ^a   Rudlowski, C ^a   Lauschner, I ^a   Schuetz, F ^a   Egerer, G ^a   Haas, R ^c   Ho, A D ^a   Bastert, G ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Institute for Gynecological Oncology   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

High dose chemotherapy; Micrometastatic bone marrow cells; Primary breast cancer; Prognostic impact; Survival

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; GOSERELIN; IFOSFAMIDE; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEIN P53; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; THIOTEPA;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AXILLARY LYMPH NODE; BONE MARROW BIOPSY; BONE MARROW CELL; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MONONUCLEAR CELL; MULTIVARIATE ANALYSIS; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT;

EID: 9444249988     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh433     Document Type: Article

References (30)

1. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1143.
2. Gianni AM, Sienu S, Bregni M et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary lymph nodes: five years results. J Clin Oncol 1997; 15: 2312-2321.
3. Bergh J, Wiklund T, Erikstein B et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Lancet 2000; 356: 1384-1391.
4. Hortobagyi GN, Buzdar AU, Theriault RL et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 2000; 92: 225-233.
5. Schrama JG, Faneyte IF, Schornagel JH et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years follow-up. Ann Oncol 2002; 13: 689-698.
6. Zander AR, Kröger N, Schmoor C et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol 2004; 22: 2273-2283.
7. Rodenhuis S, Bontenbal M, Beex LV et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003; 349: 7-16.
8. Tallman MS, Gray R, Robert NJ et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 2003; 349: 17-26.
9. Harbeck N, Untch M, Pache L, Eiermann W. Tumor cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer 1994; 69: 566-571.
10. Diel IJ, Kaufmann M, Costa SD et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996; 88: 1652-1664.
11. Braun S, Pantel K, Müller P et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000; 342: 525-533.
12. Gerber B, Krause A, Müller H et al. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol 2001; 19: 960-971.
13. Gebauer G, Fehm T, Merkle E et al. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 2001; 19: 3669-3674.
14. Wiedswang G, Borgen E, Kåresen R et al. Detection of isolated tumor cells in bone marrow is an independent prognostic actor in breast cancer. J Clin Oncol 2003; 21: 3469-3478.
15. Braun S, Vogl FD, Schlimok G et al. Pooled analysis of prognostic impact of bone marrow micrometastasis: 10-year survival of 4199 breast cancer patients. Breast Cancer Res Treat 2003; 82 (Suppl 1): S8 (Abstr).
16. Salvadori B, Squicciarini P, Rovini D et al. Use of monoclonal antibody MBr1 to detect micrometastases in bone marrow specimens of breast cancer patients. Eur J Cancer 1990; 26: 865-867.
17. Singletary SE, Larry L, Tucker SL, Spitzer G. Detection of micrometastatic tumor cells in bone marrow of breast carcinoma patients. J Surg Oncol 1991; 47: 32-36.
18. Courtemanche DJ, Worth AJ, Coupland RW et al. Monoclonal antibody LICR-LON-M8 does not predict the outcome of operable breast cancer. Can J Surg 1991; 34: 21-26.
19. Molino A, Pelosi G, Turazza M et al. Bone marrow micrometastases in 109 breast cancer patients: correlations with clinical and pathological features and prognosis. Breast Cancer Res Treat 1997; 42: 23-30.
20. Hohaus S, Pforsich M, Murea S et al. Immunomagnetic selection of CD34+ peripheral blood stem cells for autografting in patients with breast cancer. Br J Haematol 1997; 97: 881-888.
21. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 47: 457.
22. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Star Soc (A) 1972; 135: 185-196.
23. Cox DR. Regression models and life tables. J R Stat Soc (B) 1972; 34: 187-220.
24. Fields KK, Elfenbein GJ, Trudeau WL et al. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996; 14: 1868-1876.
25. Vredenburgh JJ, Silva O, Broadwater G et al. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. Biol Blood Marrow Transplant 1997; 3: 91-97.
26. Braun S, Kentenich C, Janni W et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer. J Clin Oncol 2000; 18: 80-86.
27. Nieto Y, Cagnoni PJ, Shpall EJ et al. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. Clin Cancer Res 1999; 5: 3425-3431.
28. Nieto Y, Cagnoni PJ, Nawaz S et al. Evaluation of the predictive value of her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 2000; 18: 2070-2080.
29. Hensel M, Schneeweiss A, Sinn HP et al. P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support. Int J Cancer 2002; 100: 290-296.
30. Somlo G, Simpson J, Doroshow J et al. Prognostic indicators and 7-year outcome following high-dose chemotherapy versus conventional adjuvant chemotherapy in high-risk primary breast cancer. Proc Am Soc Clin Oncol 2001; 20: 11b (Abstr).